Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 3Withdrawn 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Neurofibroma, Plexiform 1Metastatic Solid Tumors. 1Melanoma 1Lymphoma 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Acute 1Hematologic Diseases 1Gastrointestinal Stromal Tumors 1Dermoid Cyst 1Burkitt Lymphoma 1Blast Crisis 1

Interventions

fludarabine 2Busulfan 2pembrolizumab 1merphos 1itacitinib 1Thiotepa 1Tacrolimus 1Pam2CSK4 acetate and ODN M362 combination 1Methotrexate 1Melphalan 1Lenalidomide 1Imatinib Mesylate 1INCB039110 1Granulocyte Colony-Stimulating Factor 1Cytarabine 1Cyclophosphamide 1Cladribine 1Bone Marrow Transplantation 1Blood Specimen Collection 1AP 1903 reagent 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Hematologic Diseases × Imatinib Mesylate × Clear all
NCT00594555 2008-10-31

A Study Evaluating the Effects of CLAG With Gleevec in Refractory or Relapsed Acute Myeloid Leukemia

University of Cincinnati

Phase 2 Withdrawn
20 enrolled
MyeloidOther hematologic neoplasm

Blast Crisis, Hematologic Diseases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡